Atila PGx Cardiovascular SNP Panel (Cardiovascular, Anticoagulation & Statin Response)
Response to cardiovascular drugs is strongly modulated by common variants. CYP2C19 loss-of-function alleles reduce clopidogrel activation and raise cardiovascular event risk; CYP2C9, VKORC1, and CYP4F2 jointly drive warfarin dose requirements; and SLCO1B1 (plus ABCG2) predicts statin-induced myopathy. The panel also covers F2 (prothrombin G20210A) and F5 (Factor V Leiden) for inherited thrombophilia, giving a self-contained cardiovascular/anticoagulation/statin workup.
Features Include
Technical Specs
Workflow Overview for the Atila PGx Cardiovascular SNP Panel (Cardiovascular, Anticoagulation & Statin Response)
This section is for demonstrative purposes only and may be incomplete or inaccurate. Always refer to the product instructions for precise guidelines and directions.
Prepare the sample–master mix
For each sample, combine 2 µL of PCR master mix with 1 µL of genomic DNA to make a 3 µL-per-reaction mix. Scale the volume to the number of assay wells required for that sample.
Load the panel plate
Dispense the combined master mix–sample mixture into each assay well of the pre-arrayed panel plate. Seal the plate and briefly centrifuge to collect the reaction at the bottom of each well.
Run real-time PCR
Load the plate onto a Bio-Rad CFX or Applied Biosystems Quant Studio real-time PCR system and run the standard PCR cycling protocol.
Data analysis
Import the run file into the accompanying analysis software for automated allele calling and genotype determination across all panel SNPs.
Obtain result report
The software generates a structured pharmacogenetics report translating each genotype into gene-level phenotype and drug-response context.

